Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 6, 2010, Pages 2560-2566

  Jordan, Robert ^a   Chinsangaram, Jarasvech ^a   Bolken, Tove C ^a   Tyavanagimatt, Shanthakumar R ^a   Tien, Deborah ^a,d   Jones, Kevin F ^a   Frimm, Annie ^a   Corrado, Michael L ^b   Pickens, Margaret ^b   Landis, Patrick ^b   Clarke, Jean ^a   Marbury, Thomas C ^c   Hruby, Dennis E ^a  

^a SIGA Technologies Incorporated   (United States)

^b SYNEOS HEALTH   (United States)

^c ORLANDO CLINICAL RESEARCH CENTER   (United States)

^d BAXTER HEALTHCARE CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; PLACEBO; ST 246; TECOVIRIMAT; UNCLASSIFIED DRUG;

ABNORMAL SENSATION; ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISTRIBUTION VOLUME; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG HALF LIFE; DRUG SAFETY; DRUG WITHDRAWAL; EYE DISEASE; FATIGUE; FEMALE; FLATULENCE; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; TIME TO MAXIMUM PLASMA CONCENTRATION; URTICARIA; XEROSTOMIA;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTIVIRAL AGENTS; BENZAMIDES; DOUBLE-BLIND METHOD; FEMALE; HALF-LIFE; HUMANS; ISOINDOLES; MALE; MIDDLE AGED; ORTHOPOXVIRUS; POXVIRIDAE INFECTIONS; YOUNG ADULT;

EID: 77952642017     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01689-09     Document Type: Article

References (12)

1. Bailey, T. R., S. R. Rippin, E. Opsitnick, C. J. Burns, D. C. Pevear, M. S. Collett, G. Rhodes, S. Tohan, J. W. Huggins, R. O. Baker, E. R. Kern, K. A. Keith, D. Dai, G. Yang, D. Hruby, and R. Jordan. 2007. N-(3,3a,4,4a,5,5a,6,6a- octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2-(1H)-yl)carboxamides: identification of novel orthopoxvirus egress inhibitors. J. Med. Chem. 50:1442-1444.
2. Bray, M. 2003. Pathogenesis and potential antiviral therapy of complications of smallpox vaccination. Antiviral Res. 58:101-114.
3. Fenner, F., D. A. Henderson, I. Arita, Z. Jazek, and I. D. Ladnyi. 1988. Smallpox and its eradication. World Health Organization, Geneva, Switzerland.
4. Institute of Medicine. 1999. Assessment of future scientific needs for live variola virus. National Academy Press, Washington, DC.
5. Jordan, R., D. Tien, T. C. Bolken, K. F. Jones, S. R. Tyavanagimatt, J. Strasser, A. Frimm, M. L. Corrado, P. G. Strome, and D. E. Hruby. 2008. Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor. Antimicrob. Agents Chemother. 52:1721-1727.
6. LeDuc, J. W., and P. B. Jahrling. 2001. Strengthening national preparedness for smallpox: an update. Emerg. Infect. Dis. 7:155-157.
7. Parker, S., A. Nuara, R. M. Buller, and D. A. Schultz. 2007. Human monkeypox: an emerging zoonotic disease. Future Microbiol. 2:17-34. (Pubitemid 46766996)
8. Quenelle, D. C., R. M. Buller, S. Parker, K. A. Keith, D. E. Hruby, R. Jordan, and E. R. Kern. 2007. Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. Antimicrob. Agents Chemother. 51:689-695.
9. Sbrana, E., R. Jordan, D. E. Hruby, R. I. Mateo, S. Y. Xiao, M. Siirin, P. C. Newman, A. P. A. Travassos da Rosa, and R. B. Tesh. 2007. Efficacy of the antipoxvirus compound ST-246 for treatment of severe orthopoxvirus infection. Am. J. Trop. Med. Hyg. 76:768-773.
10. Trindade, G. S., G. L. Emerson, D. S. Carroll, E. G. Kroon, and I. K. Damon. 2007. Brazilian vaccinia viruses and their origins. Emerg. Infect. Dis. 13:965-972.
11. Vorou, R. M., V. G. Papavassiliou, and I. N. Pierroutsakos. 2008. Cowpox virus infection: an emerging health threat. Curr. Opin. Infect. Dis. 21:153-156.
12. Yang, G., D. C. Pevear, M. H. Davies, M. S. Collett, T. Bailey, S. Rippen, L. Barone, C. Burns, G. Rhodes, S. Tohan, J. W. Huggins, R. O. Baker, R. L. Buller, E. Touchette, K. Waller, J. Schriewer, J. Neyts, E. DeClercq, K. Jones, D. Hruby, and R. Jordan. 2005. An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus challenge. J. Virol. 79:13139-13149.